1. Red nucleus IL-33 facilitates the early development of mononeuropathic pain in male rats by inducing TNF-α through activating ERK, p38 MAPK, and JAK2/STAT3
- Author
-
Hao-Nan Li, Qing-Qing Yang, Xue Tian, Fan Feng, Yuan-Wu Zou, Wen-Tao Wang, Shu-Ting Zhang, Xiao-Yan Zeng, Jia-Xue Wang, Jun-Yang Wang, and Yu-Tong Xia
- Subjects
0301 basic medicine ,MAPK/ERK pathway ,Male ,STAT3 Transcription Factor ,SNi ,Red nucleus ,MAP Kinase Signaling System ,p38 mitogen-activated protein kinases ,Immunology ,Mononeuropathic pain ,Pharmacology ,p38 Mitogen-Activated Protein Kinases ,Proinflammatory cytokine ,Rats, Sprague-Dawley ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,0302 clinical medicine ,medicine ,Animals ,Receptor ,RC346-429 ,Microglia ,business.industry ,Tumor Necrosis Factor-alpha ,Signaling pathway ,General Neuroscience ,Research ,Mononeuropathies ,Janus Kinase 2 ,Interleukin-33 ,Rats ,Tumor necrosis factor-α ,030104 developmental biology ,medicine.anatomical_structure ,Neurology ,Neuralgia ,Tumor necrosis factor alpha ,Neurology. Diseases of the nervous system ,business ,030217 neurology & neurosurgery - Abstract
Background Our recent studies have identified that the red nucleus (RN) dual-directionally modulates the development and maintenance of mononeuropathic pain through secreting proinflammatory and anti-inflammatory cytokines. Here, we further explored the action of red nucleus IL-33 in the early development of mononeuropathic pain. Methods In this study, male rats with spared nerve injury (SNI) were used as mononeuropathic pain model. Immunohistochemistry, Western blotting, and behavioral testing were used to assess the expressions, cellular distributions, and actions of red nucleus IL-33 and its related downstream signaling molecules. Results IL-33 and its receptor ST2 were constitutively expressed in the RN in naive rats. After SNI, both IL-33 and ST2 were upregulated significantly at 3 days and peaked at 1 week post-injury, especially in RN neurons, oligodendrocytes, and microglia. Blockade of red nucleus IL-33 with anti-IL-33 neutralizing antibody attenuated SNI-induced mononeuropathic pain, while intrarubral administration of exogenous IL-33 evoked mechanical hypersensitivity in naive rats. Red nucleus IL-33 generated an algesic effect in the early development of SNI-induced mononeuropathic pain through activating NF-κB, ERK, p38 MAPK, and JAK2/STAT3, suppression of NF-κB, ERK, p38 MAPK, and JAK2/STAT3 with corresponding inhibitors markedly attenuated SNI-induced mononeuropathic pain or IL-33-evoked mechanical hypersensitivity in naive rats. Red nucleus IL-33 contributed to SNI-induced mononeuropathic pain by stimulating TNF-α expression, which could be abolished by administration of inhibitors against ERK, p38 MAPK, and JAK2/STAT3, but not NF-κB. Conclusions These results suggest that red nucleus IL-33 facilitates the early development of mononeuropathic pain through activating NF-κB, ERK, p38 MAPK, and JAK2/STAT3. IL-33 mediates algesic effect partly by inducing TNF-α through activating ERK, p38 MAPK and JAK2/STAT3.
- Published
- 2021